Fda
FDA-approved drugs and research would count as medical use
Representative Steve Cohen’s bill also says a substance can qualify when it is a recognized legitimate medical use in a state, so long as local regulators back that view with evidence-based review. The measure is now in committee.
A House proposal would write a new test for when a drug or substance has accepted medical use under federal law. That definition could affect research, treatment access and how the government handles scheduling.
- The bill would define “accepted medical use” inside the Controlled Substances Act.
- FDA-approved drugs, scientific research and some state-recognized uses would all count.
- It also adds definitions for dependence and physical dependence.
- The change could affect research, treatment access and how federal drug law is applied.
- A drug can be a treatment, a lab tool or a controlled substance, and the label matters when federal law decides what doctors can use and what researchers can study
A drug can be a treatment, a lab tool or a controlled substance, and the label matters when federal law decides what doctors can use and what researchers can study. In Washington, Tennessee Rep. Steve Cohen’s bill would write a new definition of “accepted medical use” into the Controlled Substances Act, the federal law that still shapes how the government treats controlled substances.
The bill says that term would include drugs or other substances used under approval from the Food and Drug Administration, or FDA, or under licensure from the Public Health Service Act. It would also cover scientific research aimed at understanding human biology, developing new therapies, or studying animal or human models of disease, syndrome or disorder.
Three ways a drug could qualify
The proposal gives accepted medical use three lanes. The first is the most familiar: a drug used in line with FDA approval or Public Health Service Act licensure. The second is research, which the bill names directly instead of leaving as an implied exception buried in federal practice.
The third lane is narrower and tied to the states. A drug or substance could count if a jurisdiction has authorized it for medical use, it is widely used there by health care practitioners, and the local medical regulators recognize that use through evidence-based scientific evaluation using rigorous and generally accepted methods.
That does not make the bill a free pass for any specific substance, and it does not by itself reschedule anything. It gives federal law a clearer way to say when a use is medical, when it is research and when a state-recognized practice deserves a place in the conversation.
The words that drive enforcement
The bill does more than rename one term. It also adds definitions for dependence liability, physical dependence, psychological dependence, abuse, potential for abuse, misuse and potential benefits to society. Those labels are the kind that can quietly shape how federal drug law is read long before anyone gets to a courtroom or a clinic.
One of the sharper changes is the physical-dependence language, which ties the term to bodily adaptation after repeated, chronic use and to withdrawal symptoms. The bill also says the attorney general should defer to the health secretary’s scientific and medical evaluation when carrying out scheduling decisions, and should tailor controls to protect public health and safety while preserving access for accepted medical uses.
That is the kind of statutory cleanup that can look technical on the page and still matter a great deal in practice. When the language around medical use gets clearer, so do the arguments over research, treatment access and how much room federal law leaves for legitimate medical work.